Key result
In patients with chronic kidney disease undergoing coronary artery bypass grafting, intraoperative infusion of human atrial natriuretic peptide significantly improved the 10-year postoperative dialysis-free rate to 97.8% compared to 90.1% with placebo (p=0.0014).
Why the study?
Does human atrial natriuretic peptide improve postoperative dialysis avoidance and renal function in non-dialysis CKD patients undergoing CABG?
RCT (n=303)
Double-blind
Randomized (lottery method)
No
Does human atrial natriuretic peptide improve postoperative dialysis avoidance and renal function in non-dialysis CKD patients undergoing CABG?
Absolute Event Rate: 97.8% vs 90.1%
p-value: p=0.0014
In non-dialysis CKD patients undergoing CABG, hANP administration significantly reduces the long-term need for dialysis and postoperative cardiac events.
Supports intraoperative hANP in non-dialysis CKD patients undergoing CABG to reduce long-term dialysis risk; extends randomized evidence to 10-year renal outcomes.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Kimura et al. (2012) conducted an RCT in Chronic kidney disease (CKD) undergoing coronary artery bypass grafting (CABG) (n=303). Human atrial natriuretic peptide (hANP) vs. Placebo was evaluated on Postoperative dialysis-free rate at 10 years (p=0.0014). In patients with chronic kidney disease undergoing coronary artery bypass grafting, intraoperative infusion of human atrial natriuretic peptide significantly improved the 10-year postoperative dialysis-free rate to 97.8% compared to 90.1% with placebo (p=0.0014).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: